Pardes Biosciences is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for gastrointestinal and liver diseases. The company leverages its proprietary drug discovery platform to target the microbiome and other pathways involved in disease pathogenesis.

Pardes Biosciences

Techahead is a self-described global leader in providing IT staffing and consulting services.  They offer solutions for various IT needs.

Techahead

Foresite Capital is a multi-stage healthcare and life sciences investment firm with ~ $3.5B in assets under management (as of 12/31/23). The firm aims to address areas of great unmet need by funding promising healthcare and life sciences businesses at all stages of their life cycles. Foresite Capital uses a data science-driven approach to invest in companies that leverage biology and big data to transform healthcare, including 10x Genomics, Relay Therapeutics, Element Biosciences, Inscripta, as well as companies developing next generation therapeutics. Founded in 2011, Foresite Capital is based in San Francisco. 

Intellia Therapeutics

Jounce Therapeutics

SAGE Therapeutics

Solid Biosciences

SomaLogic

Vaxcyte

Twist Bioscience

10X Genomics

23andMe

Invivyd

Adaptimmune

Alector

Fulcrum Therapeutics

Verona Pharma

Arcus Biosciences

Orchard Therapeutics

Protagonist Therapeutics

Quantum SI

REGENXBIO

Relay Therapeutics

Replimune Group

Foresite Capital

We're happy to see our colleague Shoman Kasbekar included in this piece in the Biomarker newsletter covering rising stars in biotech investing and creation, how they got started, and lessons learned. Shoman shares his perspective on how the success of the investment only begins with the investment itself. Read more at the link below. 

Our managing director Vik Bajaj sat down with Maneesh Jain at portfolio company Mirvie for a conversation on the maternal health crisis, and why precision medicine represents the future of pregnancy health. Mirvie aims to predict pregnancy complications before they happen by using RNA messages to reveal the underlying biology of pregnancy health. We welcome your comments on this important conversation!

#maternalhealth #pregnancy #precisionmedicine

Our head of research, Scott McIsaac, sat down with former Foresite Labs Fellow and current associate Chase Kelley recently to discuss his experiences participating in the joint Foresite Capital & Foresite Labs Fellows program. Check it out at the link below. We are now accepting applications for our next cohort: https://lnkd.in/gJuaCbPR

#lifesciences #fellowships #healthcare #foresitelabs

Metric
Company Name	Pardes Biosciences	Techahead
Symbol
MSH ID	COM:FORESITECAPITAL	COM:TECHAHEAD
Market	PRIVATE	PRIVATE
Sector	Healthcare & Health Services	Technology
Industry	Biotechnology	Information Technology and Services
Country	US	US
Stage
Employee Count	62
Website	foresitecapital.com	techahead.com
LinkedIn	foresite-capital-management
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:FORESITECAPITAL

Pardes Biosciences

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue